# Creyon Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/creyon-bio

- Industry: Pharmaceuticals
- Headquarters: Sam Diego, US
- Website: www.creyonbio.com
- Latest round: Series A (Mar 8, 2022)
- Investors on record: 5

## About

Based in California, US, and founded in 2019 by its CEO Chris Hart and CSO Swagatam, Creyon Bio, Inc. operates as a drug development platform. In March 2022, Creyon Bio, Inc. raised an undisclosed amount of series A funding co-led by new investors DCVC Bio and Lux Capital, with participation from other new investors Casdin Capital, Alexandria Venture Investments.

Creyon Bio operates as a drug company that provides (ribonucleic acid) RNA-based medicines and oligonucleotide-based medicines (OBMs) which are used in various respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The company’s offerings include purpose-built datasets that feed into sophisticated machine learning models, quickly discovering design rules and engineering principles for safe and effective OBMs (Oligonucleotide-based medicines).

The company plans to use the March 2022 funding to further enhance its platform, expand the team, and lay the foundations for a diverse internal pipeline.

## Funding rounds

- Series A, Mar 8, 2022 — Alexandria Venture Investments, Lux Capital, Casdin Capital, DCVC, BioBrit

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- BioBrit — Series A